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singly used in antitumoral therapies and mTOR inhibition with rapamycin
was shown to be cardioprotective during aging and cardiac stress. Studies
in genetic mice models have shown that mTOR is essential for heart devel-
opment and cardiac function in adult. However, mTOR functions during
postnatal cardiac development are not fully elucidated. We have therefore
generated a cardiac-specific mTOR knockout mouse using α-MHC-Cre
mice leading to mTOR inactivation in early postnatal mouse myocardium.
The mutant mice develop a severe lethal dilated cardiomyopathy due to
defects in cardiomyocyte growth, survival and subsequent fibrosis. In
contrast to adult myocardium, both mTORC1 and mTORC2 activities are
impaired in juvenile heart, as shown by hypophosphorylation of the trans-
lation inhibitor 4E-BP1 and loss of the cardioprotective AKTS473 phos-
phorylation. We find that translation initiation defects and altered ribosome
biogenesis both contribute to impaired cardiomyocyte growth. In addition,
we show that increased apoptosis is associated with activation of JNK
kinase and p53 accumulation. Moreover mTORcmKO hearts display a
strong decreased expression of the primary oxygen carrier, myoglobin, and
HIF1α accumulation suggesting hypoxia. However, mTORcmKO hearts do
not display HIF1 hypoxic response consistently with mTOR being essential
for HIF1-dependant trancriptionnal activity. These observations indicate
that hypoxia-induced apoptosis likely contribute to DCM in mTORcmKO
mice. Altogether, our results demonstrate that mTOR is a key regulator of
cardiomyocyte growth, viability and oxygen supply in early postnatal myo-
cardium. Our findings highlight potential cardiotoxicity of new mTOR
inhibitors and the importance to set up optimal treatments in cardiology to
both target mTOR hypertrophic functions and maintain adequate oxygen
supply.
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The bone derived hormone fibroblast growth factor 23 (FGF23) and its co-
receptor Klotho represent a novel endocrine axis regulating mineral metabo-
lism in health and disease.
FGF23-Klotho signalling inhibits renal phosphate reabsorption and activa-
tion of vitamin D, and reduces secretion of parathyroid hormone. Serum levels
of FGF23 rise in chronic kidney disease (CKD). In contrast, tissue expression
of Klotho decreases in parallel with CKD progression and reaches low or
undetectable levels in end stage renal disease.
Numerous studies identify elevated FGF23 as a predictor of adverse clin-
ical outcome. In particular, elevated FGF23 has recently been associated with
greater risks of major cardiovascular events and mortality.
However, there have been very few studies that have attempted to
address the direct effects of FGF23 on myocardium. Moreover whether
Klotho is involved in FGF23 – mediated actions on cardiomyocytes is still
unclear.
In this context, we investigate the role of FGF23 and Klotho in adult rat
ventricular myocytes (ARVMs). Using video-edge-detection, epifluorescent
microscopy and an Ionoptix® system, performed in isolated cardiomyocytes
subjected to FGF23 or Klotho alone, or in association, we showed that FGF23
increases cell size and cell shortening in ARVMs, and induces arrhythmia in
the presence of Isoprenaline. In addition Klotho prevents FGF23 effects on
adult cardiomyocytes. Indeed, ARVMs subjected to Klotho showed marked
protection from FGF23-induced hypertrophic responses and from FGF23-
induced arrhythmias in the presence of Isoprenaline.
Altogether these preliminary data provide a direct evidence of the role
FGF23 in adult cardiomyocytes and suggest that Klotho may have a beneficial
effect in preventing adverse cardiovascular outcomes in patients with or
without CKD.
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The rough endoplasmic reticulum (rER) is the site for synthesis, folding and
quality control of secreted and membrane proteins. Impairment of ER function in
response to stresses such as oxidative stress, disruption of calcium homeostasis or
ischemia causes the accumulation of misfolded proteins in the rER lumen,
resulting in ER stress. Over the past decade, ER stress has emerged as an impor-
tant mechanism involved in the pathogenesis of cardiovascular diseases including
heart failure. However, the molecular mechanisms underlying the contribution of
ER stress to cardiac dysfunction remain poorly understood. In the present study,
we evaluated the effect of the ER stressor tunicamycin (TN) on cardiac function
in mice. TN injection (2mg/kg, 72h) induced a significant impairment of systolic
function as indicated by the decrease in ejection fraction and fractional shortening.
However, the heart rate, left ventricular internal diameters in diastole and systole
and wall thickness were not affected. Transmission electron microscopy analysis
revealed that TN induced an important ultrastructural remodeling of the cardiomy-
ocytes with an increase in the occurrence of rER. Whereas rER was essentially
located near the nucleus in cardiomyocytes of control mice, we observed an
expansion of the rER network near sarcomeres and around T-tubules and mito-
chondrial clusters after TN treatment. In addition, mitochondrial structure and net-
work were also disorganized. When measured in skinned fibers, the rate of
mitochondrial oxidation was slower and an impairment of the function of the cre-
atine kinase energy shuttle was observed in response to TN. In addition, ER stress
triggered a metabolic remodeling characterized by a shift from fatty acid to glyco-
genic substrates consumption. Taken together our results show for the first time
that the cytoarchitectural and metabolic alterations of cardiomyocytes contribute to
the cardiac injury induced by ER stress.
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The heart is highly energy-dependent with most of its energy provided by
mitochondria. Mitochondria also play a role in many essential cellular processes
including metabolite synthesis, redox balance, calcium homeostasis and cell death.
Therefore, maintaining a functional population of mitochondria is critical for car-
diac function and identification of novel regulatory mechanisms. Recently, a sol-
uble adenylyl cyclase (sAC) has been revealed to serve as a local source of the
second messenger cAMP in the mitochondrial matrix in response to bicarbonate
and calcium. PDE2A, a cGMP-stimulated cAMP-hydrolyzing phosphodiesterase
(PDE), was also shown to be expressed in the mitochondrial matrix of liver and
brain. To gain new insights into the control of mitochondrial pool of cAMP, we
investigated the role of various isoforms of PDEs in isolated cardiac mitochondria.
Western blot analysis of PDE protein expression revealed positive bands for
PDE2A, 3A, 4A and 4B subtypes in cardiac mitochondria. Basal cAMP-degrading
enzymatic activities were determined by radioenzymatic assay in cardiac mito-
chondrial lysates with 1μm cAMP as substrate. PDE2 represented the largest mito-
chondrial cAMP PDE activity (35% of total) and its activity was enhanced ~2-fold
by 5μM cGMP and was inhibited by the PDE2 inhibitor, Bay 60-7550 (100nm).
PDE3 and PDE4 activities represented, respectively, 30% and 25% of total, and
they were inhibited by their respective inhibitors, cilostamide (1μm) and Ro 20-
1724 (10 μM). Accordingly, measurements by ELISA of mitochondrial cAMP
levels confirmed that inhibition of PDE2, 3 and 4 families leads to an increase in
cAMP level. In conclusion, at least three PDE families and four PDE subtypes are
located in the cardiac mitochondrial matrix, participating to a local signaling
pathway with sAC to control cAMP level. Our findings unravel a cAMP signaling
cascade in cardiac mitochondria which may have implications for the metabolic
control of cardiac function.
